LawrenceHao-WenLuMD

Research • South San Francisco, CA

Oncology Clinical Development (Industry)

Join to view full profile

Dr. Lu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lu's full profile

Already have an account?

Office
121 Oyster Point Blvd
South San Francisco, CA 94080

Education & Training

University of ColoradoFellowship, Nephrology, 2006 - 2009
University of ColoradoResidency, Internal Medicine, 2003 - 2006
Johns Hopkins University School of MedicineClass of 2003

Certifications & Licensure

CA State Medical License 2008 - 2020
NV State Medical License 2010 - 2015

Clinical Trials

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors Start of enrollment: 2019 Nov 20
Terminated
Phase 2
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL Start of enrollment: 2018 Jun 15
Completed
Phase 1, Phase 2
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Start of enrollment: 2020 Jun 30
Terminated
Phase 3
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors Start of enrollment: 2022 Feb 22
Recruiting
Phase 1
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma Start of enrollment: 2017 Nov 16
Active, not recruiting
Phase 3
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Oct 15
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

17 citations
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding...
Rachel E. Sanborn, Omid Hamid, Elisabeth G.E. de Vries, Patrick A. Ott, Javier Garcia-Corbacho
Journal for Immunotherapy of Cancer. 2021-07-01
47 citations
Depletion of macrophages and dendritic cells in ischemic acute kidney injury.
Lawrence Lu, Sarah Faubel, Zhibin He, Ana Andres Hernando, Alkesh Jani
American Journal of Nephrology. 2012-01-25
15 citations
Macrophages are not the source of injurious interleukin-18 in ischemic acute kidney injury in mice
Zhibin He, Belda Dursun, Dong-Jin Oh, Lawrence Lu, Sarah Faubel
American Journal of Physiology. Renal Physiology. 2009-01-07

Grant Support

The Role Of Macrophages And Natural Killer Cells In Cisplatin-Induced Acute RenalNational Institute Of Diabetes And Digestive And Kidney Diseases2007